BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $54,905,000 | – | 2,035,790 | – | 1.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $82,353,000 | 42.93% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $792,257,000 | 4.46% |
| Perceptive Advisors | 6,706,268 | $143,983,000 | 3.88% |
| Cormorant Asset Management, LP | 2,617,566 | $56,199,000 | 3.42% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $571,553,000 | 2.98% |
| SC US (TTGP), LTD. | 2,544,738 | $54,636,000 | 2.42% |
| HHLR ADVISORS, LTD. | 4,388,690 | $94,225,000 | 1.30% |
| Fernwood Investment Management, LLC | 95,200 | $2,044,000 | 1.01% |
| AMERICAN INTERNATIONAL GROUP, INC. | 6,746,511 | $144,847,000 | 0.58% |
| Ratan Capital Management LP | 46,548 | $999,000 | 0.53% |